Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 9:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1297–1320 of 15,129 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Randomized Controlled Study Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Study Of PF-06700841, With Bioavailability/Food Effect Investigation

NCT02310750
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
PF-06700841 oral solution/suspension, Placebo, PF-06700841 tablet
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Mar 8, 2017 · Synced Oct 25, 2026, 9:53 PM EDT
Completed Phase 2 Interventional Results available

A Randomized, Vehicle-Controlled Study of 2 Concentrations of A-101 for the Treatment of Seborrheic Keratosis

NCT03148691
View directory record Official record
Conditions
Seborrheic Keratosis
Interventions
A-101
Drug
Lead sponsor
Aclaris Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
253 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
9
States / cities
Washington D.C., District of Columbia • Miami, Florida • Newnan, Georgia + 6 more
Source: ClinicalTrials.gov public record
Updated May 6, 2019 · Synced Oct 25, 2026, 9:53 PM EDT
Completed Phase 2 Interventional

Induction and Maintenance Study of BMS-936557 in Patients With Moderate to Severely Active Crohn's Disease

NCT01466374
View directory record Official record
Conditions
Crohn's Disease
Interventions
Placebo, BMS-936557 (Anti-IP-10 Antibody)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
10
States / cities
Santa Monica, California • Winter Park, Florida • Hammond, Louisiana + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2015 · Synced Oct 25, 2026, 9:53 PM EDT
Completed Not applicable Interventional

AM for Refractory Achilles Tendinopathy

NCT06172218
View directory record Official record
Conditions
Achilles Tendinopathy
Interventions
Flo, Saline
Other
Lead sponsor
North Park Podiatry
Other
Eligibility
18 Years to 64 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Oct 25, 2026, 9:53 PM EDT
Recruiting Phase 2 Interventional

A Phase 2, Randomized, Placebo Controlled, Multicenter, Masked Study to Evaluate the Efficacy, Safety, Tolerability, and Pharmacodynamics of Multidose APL 3007 in Combination With Syfovre/Pegcetacoplan (APL-2) in Patients Diagnosed With Geographic Atrophy Secondary to Age Related Macular Degeneratio

NCT07215390
View directory record Official record
Conditions
Geographic Atrophy Secondary to Age-related Macular Degeneration
Interventions
APL-3007, pegcetacoplan (APL-2), Placebo, Syfovre
Drug · Other
Lead sponsor
Apellis Pharmaceuticals, Inc.
Industry
Eligibility
60 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
78
States / cities
Gilbert, Arizona • Mesa, Arizona • Phoenix, Arizona + 68 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2026 · Synced Oct 25, 2026, 9:53 PM EDT
Completed No phase listed Observational

Non-Interventional Extension to Investigate Recurrence of Vulvovaginal Candidiasis and Candida Colonization

NCT02888197
View directory record Official record
Conditions
Candidiasis, Vulvovaginal, Yeast Infection, Mycoses, Moniliasis, Vulvovaginal, Vaginitis, Monilial
Interventions
Not listed
Lead sponsor
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older · Female only
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
23
States / cities
Phoenix, Arizona • Little Rock, Arkansas • San Diego, California + 18 more
Source: ClinicalTrials.gov public record
Updated Mar 2, 2018 · Synced Oct 25, 2026, 9:53 PM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Evaluate the Intramuscular Administration of Scopolamine

NCT04314713
View directory record Official record
Conditions
Medical Countermeasures, Organophosphate Poisoning
Interventions
Scopolamine Hydrobromide Trihydrate
Drug
Lead sponsor
Battelle Memorial Institute
Other
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Oct 25, 2026, 9:53 PM EDT
Terminated Phase 3 Interventional Results available

A Study of Prucalopride For Functional Constipation in Children and Teenagers

NCT04759833
View directory record Official record
Conditions
Constipation
Interventions
Prucalopride, Placebo
Drug · Other
Lead sponsor
Takeda
Industry
Eligibility
6 Months to 17 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
41
States / cities
Phoenix, Arizona • Tucson, Arizona • Anaheim, California + 32 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2024 · Synced Oct 25, 2026, 9:53 PM EDT
Completed Phase 2 Interventional

Study of Acute Uncomplicated Seasonal Influenza A in Adult Subjects

NCT02342249
View directory record Official record
Conditions
Influenza A
Interventions
VX-787 300 mg, VX-787 600 mg, Oseltamivir 75 mg, Placebo
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 64 Years
Enrollment
292 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
129
States / cities
Athens, Alabama • Birmingham, Alabama • Gulf Shores, Alabama + 126 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 25, 2026, 9:53 PM EDT
Terminated Not applicable Interventional

Study of the Safety and Effectiveness of DIAM™ Spinal Stabilization System Versus Conservative Care

NCT00456378
View directory record Official record
Conditions
Lumbar Degenerative Disc Disease
Interventions
DIAM™ Spinal Stabilization System, Conservative care
Device · Procedure
Lead sponsor
Medtronic Spinal and Biologics
Industry
Eligibility
18 Years to 70 Years
Enrollment
311 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2018
U.S. locations
29
States / cities
Scottsdale, Arizona • Beverly Hills, California • Los Angeles, California + 26 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2018 · Synced Oct 25, 2026, 9:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Safety, Tolerability, PK, and PD of PB2452 in Healthy Volunteers

NCT03492385
View directory record Official record
Conditions
Healthy
Interventions
PB2452 Infusion, Placebo - Sodium Chloride, Ticagrelor Oral Tablet - Pre-Treatment, Ticagrelor Oral Tablet - Pre-Treatment and Post-Treatment
Drug
Lead sponsor
SFJ Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Nov 4, 2024 · Synced Oct 25, 2026, 9:53 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Staccato Loxapine in Migraine (in Clinic)

NCT00489476
View directory record Official record
Conditions
Migraine
Interventions
Staccato Loxapine, Staccato Placebo
Drug
Lead sponsor
Alexza Pharmaceuticals, Inc.
Other
Eligibility
18 Years to 65 Years
Enrollment
168 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Wellesley Hills, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 6, 2017 · Synced Oct 25, 2026, 9:53 PM EDT
Completed Phase 2 Interventional Results available

A Phase 2 Study to Evaluate Analgesic Effect of IV CR845 For Pain Following Bunionectomy Surgery

NCT01789476
View directory record Official record
Conditions
Acute Pain
Interventions
CR845, Placebo
Drug
Lead sponsor
Cara Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 30, 2015 · Synced Oct 25, 2026, 9:53 PM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers

Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers

NCT06397768
View directory record Official record
Conditions
RSV Immunization
Interventions
RSVt vaccine, Diphtheria, tetanus, pertussis, poliomyelitis , Haemophilus influenzae type b, and hepatitis B vaccine, Diphtheria, tetanus, pertussis, Haemophilus influenzae type b and poliomyelitis vaccine, Hepatitis B vaccine, Streptococcus pneumoniae vaccine, Rotavirus vaccine, Measles, mumps, and rubella vaccine, Varicella virus vaccine, Placebo
Biological
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Eligibility
6 Months to 12 Months
Enrollment
2,226 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
66
States / cities
Birmingham, Alabama • Grand Bay, Alabama • Mobile, Alabama + 55 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 25, 2026, 9:53 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase 1/2a Safety and Efficacy of ALY688 Ophthalmic Solution in Subjects With Dry Eye Disease

NCT04201574
View directory record Official record
Conditions
Dry Eye Disease
Interventions
ALY688 0.1%, ALY688 0.4%, Vehicle
Drug
Lead sponsor
Allysta Pharmaceutical
Industry
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Bellevue, Washington
Source: ClinicalTrials.gov public record
Updated Jun 22, 2023 · Synced Oct 25, 2026, 9:53 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study Evaluating Dimebon in Patients With Mild to Moderate Alzheimer's Disease on Donepezil

NCT00829374
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Dimebon, Placebo comparator
Drug
Lead sponsor
Medivation, Inc.
Industry
Eligibility
50 Years and older
Enrollment
1,003 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
52
States / cities
Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2016 · Synced Oct 25, 2026, 9:53 PM EDT
Recruiting Not applicable Interventional

A Prospective Clinical Study to Evaluate the Effectiveness and Safety of Xcell Amnio MatrixTM (XAM) in the Management of Chronic Non-healing DFUs

NCT07116174
View directory record Official record
Conditions
Diabetic Foot Ulcer (DFU)
Interventions
Xcell Amnio Matrix, Standard of Care (SOC)
Biological · Drug
Lead sponsor
New Horizon Medical Solutions
Network
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
3
States / cities
Fresno, California • San Diego, California • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Oct 25, 2026, 9:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of Fasinumab (REGN475) in Healthy Japanese and Caucasian Subjects

NCT02516618
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Fasinumab, Placebo
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
20 Years to 55 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated May 12, 2016 · Synced Oct 25, 2026, 9:53 PM EDT
Terminated Phase 2 Interventional Results available

Study of Efficacy and Safety of Brodalumab Compared With Placebo in Adults With Inadequately Controlled Asthma With High Bronchodilator Reversibility

NCT01902290
View directory record Official record
Conditions
Asthma
Interventions
Placebo, Brodalumab
Biological
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 75 Years
Enrollment
421 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
73
States / cities
Birmingham, Alabama • Glendale, Arizona • Phoenix, Arizona + 64 more
Source: ClinicalTrials.gov public record
Updated Sep 21, 2022 · Synced Oct 25, 2026, 9:53 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety of and Immune Response to a Modified Vaccinia Ankara (MVA) HIV Vaccine in HIV Uninfected Adults

NCT00376090
View directory record Official record
Conditions
HIV Infections
Interventions
MVA-CMDR, Placebo
Biological
Lead sponsor
U.S. Army Medical Research and Development Command
Federal
Eligibility
18 Years to 40 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2017 · Synced Oct 25, 2026, 9:53 PM EDT
Terminated Phase 2 Interventional

Study of Nitazoxanide Tablets in the Treatment of Mild to Moderate Active Crohn's Disease

NCT00130390
View directory record Official record
Conditions
Crohn's Disease
Interventions
Nitazoxanide, Placebo
Drug · Other
Lead sponsor
Romark Laboratories L.C.
Industry
Eligibility
18 Years and older
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
13
States / cities
Tampa, Florida • Zephyrhills, Florida • Marietta, Georgia + 10 more
Source: ClinicalTrials.gov public record
Updated May 31, 2012 · Synced Oct 25, 2026, 9:53 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Radicle Health 24: A Study of Health and Wellness Products on Overall Health

NCT06989710
View directory record Official record
Conditions
Overall Health
Interventions
Placebo control 7.1.0, Health Active Product 7.1.1 usage, Health Active Product 7.1.2 usage, Placebo control 7.2.0, Health Active Product 7.2.1 usage
Dietary Supplement
Lead sponsor
Radicle Science
Industry
Eligibility
21 Years to 105 Years
Enrollment
1,700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Del Mar, California
Source: ClinicalTrials.gov public record
Updated Oct 6, 2025 · Synced Oct 25, 2026, 9:53 PM EDT
Completed Phase 2 Interventional

A Phase 2 Study of Vapendavir in Asthmatic Adults With Symptomatic Human Rhinovirus Infection

NCT02367313
View directory record Official record
Conditions
Asthma
Interventions
Vapendavir, Placebo
Drug
Lead sponsor
Biota Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
455 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
33
States / cities
Birmingham, Alabama • Flagstaff, Arizona • Bakersfield, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2018 · Synced Oct 25, 2026, 9:53 PM EDT
Enrolling by invitation Phase 3 Interventional

A Phase 3 Study Evaluating the Safety and Efficacy of TRIESENCE® (Injectable Suspension) for the Treatment of Ocular Inflammation and Pain After Ophthalmic Surgery

NCT07832552
View directory record Official record
Conditions
Postoperative Ocular Inflammation, Postoperative Ocular Pain
Interventions
Sham (No Treatment), TRIESENCE (triamcinolone acetonide injectable suspension)
Procedure · Drug
Lead sponsor
Harrow Inc
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 22, 2026 · Synced Oct 25, 2026, 9:53 PM EDT